• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

太平洋地区社群对如何提高太平洋痛风患者降尿酸治疗接受率的看法。

Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients.

作者信息

Ofanoa Samuela, Ofanoa Malakai, Tu'akoi Siobhan, Lutui Hinamaha, Heather Maryann, Goodyear-Smith Felicity

机构信息

Pacific Health Section, University of Auckland, 507, 28 Park Avenue, Grafton, Auckland, 1023, New Zealand.

Southpoint Family Doctors, Auckland, New Zealand.

出版信息

Int J Equity Health. 2025 Apr 2;24(1):91. doi: 10.1186/s12939-025-02465-8.

DOI:10.1186/s12939-025-02465-8
PMID:40176052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11967122/
Abstract

OBJECTIVES

This study aims to explore the views of Pacific people on how to improve the management of urate-lowering therapy among Pacific gout patients in South Auckland.

METHODS

The study used the Fa'afaletui model to explore the views on gout management across different perspectives of Pacific community members and health professionals working in health providers with high Pacific patient populations. Three workshops were delivered with the community and health professionals. All data were collected by note-takers and analysed using a general inductive approach. Participants were given the opportunity to review the results of the previous workshop before starting the next one.

RESULTS

The key findings from this study clustered into three key themes: [1] Gout interventions guided by Pacific frameworks and research; [2] a multifaceted approach including education, improved access to treatment and screening for gout, and strategies to help Pacific gout patients remain engaged and adherent; and [3] Pacific gout champions.

CONCLUSION

This study presents the views of community members of how to improve the uptake of urate-lowering therapy among Pacific gout patients. The community highlighted the need for a multifaceted intervention governed by a Pacific model, addressing access barriers and education for Pacific gout patients.

摘要

目标

本研究旨在探讨太平洋岛民对于如何改善南奥克兰太平洋痛风患者降尿酸治疗管理的看法。

方法

本研究采用法阿法莱图伊模型,从太平洋社区成员以及在太平洋患者数量众多的医疗机构工作的卫生专业人员的不同视角,探讨痛风管理的相关看法。与社区成员和卫生专业人员举办了三场研讨会。所有数据由记录员收集,并采用一般归纳法进行分析。在下一场研讨会开始前,参与者有机会查看上一场研讨会的结果。

结果

本研究的主要发现归纳为三个关键主题:[1] 以太平洋框架和研究为指导的痛风干预措施;[2] 多方面的方法,包括教育、改善痛风治疗和筛查的可及性,以及帮助太平洋痛风患者持续参与并坚持治疗的策略;[3] 太平洋痛风倡导者。

结论

本研究呈现了社区成员对于如何提高太平洋痛风患者降尿酸治疗接受度的看法。社区强调需要以太平洋模式为指导进行多方面干预,解决太平洋痛风患者的就医障碍和教育问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc67/11967122/1540c1dc7a72/12939_2025_2465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc67/11967122/1540c1dc7a72/12939_2025_2465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc67/11967122/1540c1dc7a72/12939_2025_2465_Fig1_HTML.jpg

相似文献

1
Pacific community's perceptions on how to improve uptake of urate-lowering therapy for Pacific gout patients.太平洋地区社群对如何提高太平洋痛风患者降尿酸治疗接受率的看法。
Int J Equity Health. 2025 Apr 2;24(1):91. doi: 10.1186/s12939-025-02465-8.
2
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.太平洋干预提高痛风患者降尿酸治疗使用率的设计与实施:研究方案。
Int J Equity Health. 2021 Dec 23;20(1):262. doi: 10.1186/s12939-021-01601-4.
3
Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.通过协作式初级保健方法,促进新西兰北地毛利人痛风的公平预防和管理。
J Prim Health Care. 2019 Jul;11(2):117-127. doi: 10.1071/HC18082.
4
Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review.旨在提高新西兰奥特亚罗瓦地区痛风治疗中别嘌醇使用率的干预措施:一项范围综述
J Prim Health Care. 2023 Mar;15(1):48-58. doi: 10.1071/HC22094.
5
Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.护士干预对降尿酸药物使用的影响:一项护士主导护理 RCT 中参与者的定性研究。
Joint Bone Spine. 2019 May;86(3):357-362. doi: 10.1016/j.jbspin.2018.10.008. Epub 2018 Oct 27.
6
Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study).缓解痛风患者达到目标血清尿酸水平的方法:在新西兰(Easy-Allo 研究)使用别嘌醇剂量模型进行非劣效性随机策略试验的方案。
BMJ Open. 2024 Aug 3;14(8):e084665. doi: 10.1136/bmjopen-2024-084665.
7
Management of Gout in a Hospital Setting: A Lost Opportunity.医院环境下痛风的管理:错失良机。
J Rheumatol. 2017 Oct;44(10):1493-1498. doi: 10.3899/jrheum.170387. Epub 2017 Aug 1.
8
Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.常规入院前降尿酸治疗和血清尿酸检测与痛风患者的住院时间缩短相关:一项全国范围内基于人群的队列研究。
Int J Rheum Dis. 2022 Feb;25(2):154-162. doi: 10.1111/1756-185X.14250. Epub 2021 Nov 18.
9
A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.一项探索卫生专业人员治疗痛风经验的定性研究:了解有效痛风管理中存在的认知障碍。
J Prim Health Care. 2016 Jun;8(2):149-56. doi: 10.1071/HC15017.
10
Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.痛风患者在开始使用或不使用秋水仙碱预防发作的降尿酸治疗时的心血管事件:一项使用初级保健、住院和死亡率关联数据的回顾性新用户队列研究。
Lancet Rheumatol. 2025 Mar;7(3):e197-e207. doi: 10.1016/S2665-9913(24)00248-0. Epub 2024 Dec 18.

引用本文的文献

1
Health Professionals' Perceptions of Pacific Co-Designed Resources for Pacific Gout Patients.医疗专业人员对为太平洋痛风患者共同设计的太平洋资源的看法。
Healthcare (Basel). 2025 Aug 22;13(17):2089. doi: 10.3390/healthcare13172089.

本文引用的文献

1
Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review.旨在提高新西兰奥特亚罗瓦地区痛风治疗中别嘌醇使用率的干预措施:一项范围综述
J Prim Health Care. 2023 Mar;15(1):48-58. doi: 10.1071/HC22094.
2
Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease: large data linkage study in New Zealand.无心血管疾病病史的成年人中痛风与心血管结局的关联:新西兰大型数据关联研究
BMJ Med. 2022 Jun 22;1(1):e000081. doi: 10.1136/bmjmed-2021-000081. eCollection 2022.
3
Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout.
欧洲和波利尼西亚痛风男性患者中痛风多基因风险评分与疾病发病年龄及痛风石性疾病的关联
Arthritis Rheumatol. 2023 May;75(5):816-825. doi: 10.1002/art.42393. Epub 2023 Mar 25.
4
Why Do Patients With Gout Not Take Allopurinol?为什么痛风患者不服用别嘌醇?
J Rheumatol. 2022 Jun;49(6):622-626. doi: 10.3899/jrheum.210950. Epub 2022 Feb 15.
5
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.太平洋干预提高痛风患者降尿酸治疗使用率的设计与实施:研究方案。
Int J Equity Health. 2021 Dec 23;20(1):262. doi: 10.1186/s12939-021-01601-4.
6
The inequity of access to health: a case study of patients with gout in one general practice.卫生保健可及性的不平等:以某一全科诊所的痛风患者为例。
N Z Med J. 2021 Oct 8;134(1543):51-58.
7
An enquiry into the crippling gout affecting Pacific Islander and Māori men in Western Sydney.探究困扰在悉尼西部的太平洋岛民和毛利男性的致残性痛风。
Int J Rheum Dis. 2021 Nov;24(11):1394-1401. doi: 10.1111/1756-185X.14222. Epub 2021 Oct 6.
8
Quality of care in people requiring hospital admission for gout in Aotearoa New Zealand: a nationwide analysis.新西兰奥塔哥地区因痛风住院患者的护理质量:一项全国性分析。
Intern Med J. 2022 Dec;52(12):2136-2142. doi: 10.1111/imj.15470. Epub 2022 Jul 6.
9
Aotearoa New Zealand Māori and Pacific Population-amplified Gout Risk Variants: Is a Separate Risk Gene at the Locus.新西兰毛利人和太平洋人口放大的痛风风险变异:在该基因座是否存在单独的风险基因。
J Rheumatol. 2021 Nov;48(11):1736-1744. doi: 10.3899/jrheum.201684. Epub 2021 Jul 1.
10
Compounding inequity: a qualitative study of gout management in an urban marae clinic in Auckland.加剧不平等:奥克兰城市毛利会堂诊所痛风管理的定性研究。
J Prim Health Care. 2021 Mar;13(1):27-35. doi: 10.1071/HC20112.